Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation (NCT04207619)
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation Using 13C Magnetic Resonance Spectroscopy.
🩺 Plain-English Summary (8th-Grade Level)
Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the treatment of persons with diabetes. The goal of this study is to determine the efficacy of our biomarker for predicting susceptibility to insulin-induced hypoglycemia. In order to accomplish this goal the investigatiors will pair our 13C magnetic resonance spectroscopy procedure to assess glial acetate metabolism, developed in the GLIMPSE study, with a hyperinsulinemic-hypoglycemic clamp procedure, developed in the HYPOCLAMP study (NCT03839511). The two procedures will be separated by a three day interval. The investigators will then correlate the participants' rates of glial acetate metabolism with their neuroendocrine responses to the hypoglycemic clamp. This proof of concept study will test the hypothesis that glial acetate metabolism is inversely proportional to the neuroendocrine response to hypoglycemia, that is, as glial acetate metabolism increases the neuroendocrine response will decrease.
Who can join: Review the eligibility criteria below.
Location: Pennington Biomedical Research Center — Baton Rouge, Louisiana
Age range: 18 Years to 40 Years
🧪 Interventions in This Study
- hyperinsulinemic-hypoglycemic clamp (OTHER)
- 13C-MRS procedure/Acetate infusion (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Pennington Biomedical Research Center — Baton Rouge, Louisiana
📞 Contact the Study Coordinator
Phone: (225) 763-3050
Email: amber.dragg@pbrc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes
- Northern Manhattan Study of Metabolism and Mind — New York, New York
- The Effect of Grocery Support Dose on Food Insecurity and Disease Control Among Covered California Members With Diabetes or Hypertension — San Francisco, California
- Eversense® Non-adjunctive Use Post Approval Study — Los Angeles, California
- Evaluating the Health Outcomes of the Joslin Why WAIT Program — Boston, Massachusetts
- Community Engagement Alliance Against Disparities — Washington D.C., District of Columbia
- Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk — Toronto, Ontario
Explore by condition: All Diabetes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.